The role of cost-effectiveness analysis in health and medicine

被引:986
|
作者
Russell, LB
Gold, MR
Siegel, JE
Daniels, N
Weinstein, MC
机构
[1] US PHS, OFF DIS PREVENT & HLTH PROMOT, WASHINGTON, DC 20201 USA
[2] RUTGERS STATE UNIV, INST HLTH HLTH CARE POLICY & AGING RES, NEW BRUNSWICK, NJ 08903 USA
[3] HARVARD UNIV, SCH PUBL HLTH, CAMBRIDGE, MA 02138 USA
[4] TUFTS UNIV, DEPT PHILOSOPHY, MEDFORD, MA 02155 USA
来源
关键词
D O I
10.1001/jama.276.14.1172
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-To develop consensus-based recommendations guiding the conduct of cost-effectiveness analysis (CEA) to improve the comparability and quality of studies. The recommendations apply to analyses intended to inform the allocation of health care resources across a broad range of conditions and interventions. This article, first in a 3-part series, discusses how this goal affects the conduct and use of analyses. The remaining articles will outline methodological and reporting recommendations, respectively. Participants.-The Panel on Cost-Effectiveness in Health and Medicine, a nonfederal panel with expertise in CEA, clinical medicine, ethics, and health outcomes measurement, was convened by the US Public Health Service (PHS). Evidence.-The panel reviewed the theoretical foundations of CEA, current practices, and alternative procedures for measuring and assigning Values to resource use and health outcomes. Consensus Process.-The panel met 11 limes during 2 1/2 years with PHS staff and methodologists from federal agencies. Working groups brought issues and preliminary recommendations to the full panel for discussion, Draft recommendations were circulated to outside experts and the federal agencies prior to finalization. Conclusions.-The panel's recommendations define a ''reference case'' cost-effectiveness analysis, a standard set of methods to serve as a point of comparison across studies, The reference case analysis is conducted from the societal perspective and accounts for benefits, harms, and costs to all parties. Although CEA does not reflect every element of importance in health care decisions, the information it provides is critical to informing decisions about the allocation of health care resources.
引用
收藏
页码:1172 / 1177
页数:6
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF ACADEMIC MEDICINE
    WADE, J
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1992, 15 (03): : 248 - 251
  • [22] COST-EFFECTIVENESS AND THE FUTURE OF MEDICINE
    SHULKIN, DJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (01): : 40 - 40
  • [23] Cost-effectiveness and pain medicine
    Benjamin W. Johnson
    Current Review of Pain, 1998, 2 (4): : 254 - 266
  • [24] Cost-Effectiveness of Exercise Is Medicine®
    Katzmarzyk, Peter T.
    CURRENT SPORTS MEDICINE REPORTS, 2011, 10 (04) : 217 - 223
  • [25] Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
    Sanders, Gillian D.
    Neumann, Peter J.
    Basu, Anirban
    Brock, Dan W.
    Feeny, David
    Krahn, Murray
    Kuntz, Karen M.
    Meltzer, David O.
    Owens, Douglas K.
    Prosser, Lisa A.
    Salomon, Joshua A.
    Sculpher, Mark J.
    Trikalinos, Thomas A.
    Russell, Louise B.
    Siegel, Joanna E.
    Ganiats, Theodore G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (10): : 1093 - 1103
  • [26] Evidence-based medicine and cost-effectiveness analysis
    Chalfin, DB
    CRITICAL CARE CLINICS, 1998, 14 (03) : 525 - +
  • [27] Intensive Care Medicine in 2050: cost-effectiveness analysis
    Michael R. Pinsky
    Andreas Valentin
    Gordon Rubenfeld
    Intensive Care Medicine, 2017, 43 : 1039 - 1040
  • [28] Intensive Care Medicine in 2050: cost-effectiveness analysis
    Pinsky, Michael R.
    Valentin, Andreas
    Rubenfeld, Gordon
    INTENSIVE CARE MEDICINE, 2017, 43 (07) : 1039 - 1040
  • [29] Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine
    Paulden, Mike
    O'Mahony, James F.
    McCabe, Christopher
    PHARMACOECONOMICS, 2017, 35 (01) : 5 - 13